Numerate: Best of both worlds

Numerate believes its in silico drug design produces less risky small molecules

Most in silico drug design technologies can generate compounds that either structurally fit a target or have desired activities. Numerate Inc.'s technology is able to do both, resulting in a greater variety of lead candidates that can provide its biotech and pharma clients a hedge against drug development risks like toxicity, clinical failures and IP crowding.

According to co-founder and CEO Guido Lanza, in silico design technologies come in two flavors: structure-based and data-driven.

Data-driven algorithms use compound and target data from literature and other sources to

Read the full 852 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE